Results 31 to 40 of about 20,100 (304)

Prophylactic or Early Use of Eculizumab and Graft Survival in Kidney Transplant Recipients With Atypical Hemolytic Uremic Syndrome in the United States: Research Letter

Canadian Journal of Kidney Health and Disease, 2021
Introduction: Among kidney transplant recipients (KTRs) with end-stage kidney disease (ESKD) due to atypical hemolytic uremic syndrome (aHUS), recurrence is associated with poor allograft outcomes. We compared graft and patient survival of aHUS KTRs with
Richard A. Plasse, Stephen W. Olson, Christina M. Yuan, Lawrence Y. Agodoa, Kevin C. Abbott, Robert Nee   +5 more
doaj   +1 more source

Thrombotic microangiopathy after kidney transplantation: Analysis of the Brazilian Atypical Hemolytic Uremic Syndrome cohort

PLoS ONE, 2021
Background Atypical Hemolytic Uremic Syndrome (aHUS) is an ultra-rare disease that potentially leads to kidney graft failure due to ongoing Thrombotic Microangiopathy (TMA).
Hong Si Nga, Lilian Monteiro Pereira Palma, Miguel Ernandes Neto, Ida Maria Maximina Fernandes-Charpiot, Valter Duro Garcia, Roger Kist, Silvana Maria Carvalho Miranda, Pedro Augusto Macedo de Souza, Gerson Marques Pereira, Luis Gustavo Modelli de Andrade   +9 more
doaj   +2 more sources

Long-term efficacy and safety of eculizumab in Japanese patients with generalized myasthenia gravis : a subgroup analysis of the REGAIN open-label extension study [PDF]

, 2019
The terminal complement inhibitor eculizumab was shown to improve myasthenia gravis-related symptoms in the 26-week, phase 3, randomized, double-blind, placebo-controlled REGAIN study (NCT01997229).
De Bleecker, Jan, Fujita, KP, Imai, T, Murai, H, O'Brien, F, Okumura, M, Shiraishi, H, Study Group, REGAIN, Suzuki, H, Suzuki, Y, Utsugisawa, K, Uzawa, A, Wang, JJ   +12 more
core   +1 more source

The long‐acting anti‐C5 ravulizumab results in C3 binding to PNH red cells similar to its parental molecule eculizumab

British Journal of Haematology, 2023
The extreme and peculiar susceptibility of paroxysmal nocturnal haemoglobinuria (PNH) red cells to activated complement is the main mechanism of intravascular haemolysis and anaemia in this acquired disease.
M. Sica, F. Barone, Caterina Nannelli, P. Ricci, L. Marano, M. De Angioletti, E. di Bona, A. Risitano, R. Notaro   +8 more
semanticscholar   +1 more source

Detection of the United States Neisseria meningitidis urethritis clade in the United Kingdom, August and December 2019 - emergence of multiple antibiotic resistance calls for vigilance. [PDF]

, 2020
Since 2015 in the United States (US), the US Neisseria meningitidis urethritis clade (US_NmUC) has caused a large multistate outbreak of urethritis among heterosexual males.
Borrow, R, Brooks, A, Campbell, H, Campbell, L, Fifer, H, Gray, S, Hughes, G, Ladhani, SN, Lekshmi, A, Lucidarme, J, Ramsay, ME, Rayment, M, Schembri, G   +12 more
core   +2 more sources

Treatment preference and quality of life impact: ravulizumab vs eculizumab for atypical hemolytic uremic syndrome

Journal of Comparative Effectiveness Research, 2023
Aim: Ravulizumab and eculizumab are complement C5 inhibitors approved for the treatment of atypical hemolytic uremic syndrome (aHUS). Ravulizumab requires less frequent infusions than eculizumab, which may reduce treatment burden. This study investigated
Teri J Mauch, Michael R. Chladek, S. Cataland, Shruti Chaturvedi, B. Dixon, Katherine Garlo, C. Gasteyger, A. Java, Jorge P. Leguizamo, L. Lloyd-Price, T. Pham, T. Symonds, I. Tomazos, Yan Wang   +13 more
semanticscholar   +1 more source

Eculizumab in Aquaporin-4-Positive Neuromyelitis Optica Spectrum Disorder.

New England Journal of Medicine, 2019
BACKGROUND Neuromyelitis optica spectrum disorder (NMOSD) is a relapsing, autoimmune, inflammatory disorder that typically affects the optic nerves and spinal cord.
S. Pittock, A. Berthele, K. Fujihara, H. Kim, M. Levy, Jacqueline Palace, I. Nakashima, M. Terzi, N. Totolyan, S. Viswanathan, Kai-Chen Wang, A. Pace, K. Fujita, R. Armstrong, D. Wingerchuk   +14 more
semanticscholar   +2 more sources

Outcomes in patients with atypical hemolytic uremic syndrome treated with eculizumab in a long-term observational study

BMC Nephrology, 2019
Background There are limited long-term outcome data in eculizumab-treated patients with atypical hemolytic uremic syndrome (aHUS). We report final results from the largest prospective, observational, multicenter study of patients with aHUS treated with ...
Jan Menne, Yahsou Delmas, Fadi Fakhouri, Christoph Licht, Åsa Lommelé, Enrico E. Minetti, François Provôt, Eric Rondeau, Neil S. Sheerin, Jimmy Wang, Laurent E. Weekers, Larry A. Greenbaum   +11 more
doaj   +1 more source

How I treat thrombotic thrombocytopenic purpura and atypical haemolytic uraemic syndrome [PDF]

, 2014
Thrombotic thrombocytopenic purpura (TTP) and atypical haemolytic uraemic syndrome (aHUS) are acute, rare life-threatening thrombotic microangiopathies that require rapid diagnosis and treatment.
Goodship, T, Scully, M
core   +1 more source

Eculizumab is a safe and effective treatment in pediatric patients with atypical hemolytic uremic syndrome [PDF]

, 2016
Atypical hemolytic uremic syndrome (aHUS) is caused by alternative complement pathway dysregulation, leading to systemic thrombotic microangiopathy (TMA) and severe end-organ damage.
Al-Akash, Samhar I, Ardissino, Gianluigi, Bedrosian, Camille L, Evans, Jonathan, Fila, Marc, Greenbaum, Larry A, Henning, Paul, Licht, Christoph, Lieberman, Kenneth V, Maringhini, Silvio, Ogawa, Masayo, Pape, Lars, Rees, Lesley, van de Kar, Nicole CAJ, Vande Walle, Johan   +14 more
core   +2 more sources